Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Sai-Hong Ignatius Ou,1 Ross A Soo21Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA; 2National University Health System and Cancer Science Institute of Singapore, SingaporeA...
Main Authors: | Ou SH, Soo RA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-10-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | https://www.dovepress.com/dacomitinib-in-lung-cancer-a-ldquolost-generationrdquo-egfr-tyrosine-k-peer-reviewed-article-DDDT |
Similar Items
-
The physical - an era bygone
by: Swapnil Paralikar
Published: (2020-07-01) -
“Brain drain” and “brain waste”: experiences of international medical graduates in Ontario
by: Lofters A, et al.
Published: (2014-05-01) -
Celiac disease and immigration in Northeastern Italy: the “drawn double nostalgia” of “cozonac” and “panettone” slices
by: Parco S, et al.
Published: (2011-05-01) -
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.
by: Ali S Abdelhameed, et al.
Published: (2019-01-01) -
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)